Perceived drug assignment and treatment outcome in smokers given nicotine patch therapy

Plain-language guide to PMID 20598833 (2010): double-blind randomized controlled trial study of Therapeutic nicotine (patch, non-peptide) in 384 participants.

Key Facts

PMID: 20598833
Journal: Journal of substance abuse treatment
Year: 2010
Study type: Randomized Controlled Trial
Authors: Bailey SR et al. (5 authors)
DOI: 10.1016/j.jsat.2010.05.013

What This Study Did, in Plain Language

What Was Tested

The paper reports a study of Therapeutic nicotine (patch, non-peptide), published as a randomized controlled trial.

This study assessed the relationship between treatment outcome and perceived drug assignment in smokers (nicotine patch [NP] or placebo) using abstinence and relapse status.

Smokers (N = 424) were randomly assigned to receive either NP or placebo as part of a study that examined the effects of combining NP with self-help programs.

Who Took Part

The study group was 384 participants.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

The participants were allocated by chance, so the Therapeutic nicotine (patch, non-peptide) group and the comparison group should start out alike.

Blinding on both sides kept the participants and researchers unaware of who received Therapeutic nicotine (patch, non-peptide).

Some participants received a placebo instead of Therapeutic nicotine (patch, non-peptide), giving a reference point.

What Was Measured

This study assessed the relationship between treatment outcome and perceived drug assignment in smokers (nicotine patch [NP] or placebo) using abstinence and relapse status.

Beliefs about drug assignment, assessed at the 12-month follow-up, were obtained from 384 participants.

The subject headings attached to it are Administration, Cutaneous, Nicotine and Smoking Cessation.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide) in 384 participants.

With several hundred people or more, it is a fairly large study for this kind of research.

The publication is from 2010 (Journal of substance abuse treatment), a journal based in United States.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.

Our Notes on the Compound

Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.

Therapeutic nicotine (patch, non-peptide) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.